UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2022
Commission File Number: 001-39446
CureVac N.V.
(Exact Name of Registrant as Specified in Its Charter)
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | x | Form 40-F | ¨ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
| Yes | ¨ | No | x |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Yes | ¨ | No | x |
On January 3, 2022, CureVac N.V. (the “Company”) issued the Company’s Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021.
The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CUREVAC N.V. | ||
| By: | /s/ Franz-Werner Haas, LLD, LLM | |
| Chief Executive Officer | ||
Date: January 3, 2022
EXHIBIT INDEX
| EXHIBIT NO. | DESCRIPTION | |
| 99.1 | Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as of June 30, 2021 |
Exhibit 99.1
CureVac N.V.
Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement
As of
June 30, 2021
CureVac N.V.
Interim Condensed Consolidated Statements of Operations and
Other Comprehensive Income (Loss)
| Six months ended June 30, | ||||||||
| 2020 | 2021 | |||||||
| (in thousands of EUR, except per share amounts) | (unaudited) | |||||||
| Revenue | 37,668 | 32,425 | ||||||
| Cost of sales | (5,076 | ) | (53,156 | ) | ||||
| Selling and distribution expenses | (1,009 | ) | (1,029 | ) | ||||
| Research and development expenses | (41,768 | ) | (236,267 | ) | ||||
| General and administrative expenses | (23,725 | ) | (50,651 | ) | ||||
| Other operating income | 7,732 | 45,234 | ||||||
| Other operating expenses | (238 | ) | (214 | ) | ||||
| Operating loss | (26,416 | ) | (263,658 | ) | ||||
| Finance income | 1,229 | 7,296 | ||||||
| Finance expenses | (10,714 | ) | (8,065 | ) | ||||
| Loss before income tax | (35,901 | ) | (264,427 | ) | ||||
| Income tax benefit/ (expense) | 1,760 | (1,329 | ) | |||||
| Net loss for the period | (34,141 | ) | (265,756 | ) | ||||
| Other comprehensive income: | ||||||||
| Foreign currency adjustments | 2 | (30 | ) | |||||
| Total comprehensive loss for the period | (34,139 | ) | (265,786 | ) | ||||
| Net loss per share (basic and diluted) | (0.35 | ) | (1.44 | ) | ||||
CureVac N.V.
Interim Condensed Consolidated Statements of Financial Position
| December 31, | June 30, | |||||||
| (in thousands of EUR) | 2020 | 2021 | ||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Non-current assets | ||||||||
| Intangible assets | 14,146 | 16,196 | ||||||
| Property, plant and equipment | 66,605 | 135,577 | ||||||
| Right-of-use assets | 33,984 | 32,527 | ||||||
| Other assets | 6,322 | 7,454 | ||||||
| Deferred tax assets | 445 | 349 | ||||||
| Total non-current assets | 121,502 | 192,103 | ||||||
| Current assets | ||||||||
| Inventories | 14,531 | 62,912 | ||||||
| Trade receivables | 1,014 | 2,592 | ||||||
| Contract assets | 808 | 2,302 | ||||||
| Other financial assets | 2,619 | 40,107 | ||||||
| Prepaid expenses and other assets | 48,289 | 145,217 | ||||||
| Cash and cash equivalents | 1,322,593 | 1,355,812 | ||||||
| Total current assets | 1,389,854 | 1,608,942 | ||||||
| Total assets | 1,511,356 | 1,801,045 | ||||||
| Equity and liabilities | ||||||||
| Equity | ||||||||
| Issued capital | 21,655 | 22,425 | ||||||
| Capital reserve | 1,334,704 | 1,726,713 | ||||||
| Treasury Shares | — | (3,022 | ) | |||||
| Accumulated deficit | (645,069 | ) | (910,825 | ) | ||||
| Other comprehensive income | 57 | 27 | ||||||
| Total equity | 711,347 | 835,318 | ||||||
| Non-current liabilities | ||||||||
| Finance liabilities | 25,189 | 26,726 | ||||||
| Lease liabilities | 26,853 | 25,825 | ||||||
| Contract liabilities | 500,061 | 98,891 | ||||||
| Other liabilities | 284 | 284 | ||||||
| Total non-current liabilities | 552,387 | 151,726 | ||||||
| Current liabilities | ||||||||
| Lease liabilities | 3,234 | 3,143 | ||||||
| Trade and other payables | 21,685 | 76,569 | ||||||
| Other liabilities | 64,326 | 78,602 | ||||||
| Income taxes payable | 392 | 204 | ||||||
| Contract liabilities | 157,985 | 655,483 | ||||||
| Total current liabilities | 247,622 | 814,001 | ||||||
| Total liabilities | 800,009 | 965,727 | ||||||
| Total equity and liabilities | 1,511,356 | 1,801,045 | ||||||